Introduction
Neointima formation resulting from injury to the vessel wall, induced by percutaneous transluminal coronary angioplasty (PTCA), significantly compromises the longterm success of this intervention. 1 The arterial wall responds to injury by an up-regulation of growth factors and inflammatory cytokines. 2 This results in migration of smooth muscle cells (SMC) from the media to the intima, where they continue to proliferate and deposit extracellular matrix (ECM) resulting in neointima development. 3 In vivo gene delivery aimed to inhibit SMC proliferation has been extensively studied in various animal models of neointima formation. Overexpression of cell cycle inhibitors, [4] [5] [6] [7] [8] [9] [10] [11] suicide genes, 12, 13 and growth factor antagonists 14, 15 induce various degrees of suppression of intimal thickening. Since these studies have not been able to suppress neointima formation completely, we have directed our attention to inhibition of cell migration. detectable expression of ATF.BPTI mRNA and protein in the vessel wall. Morphometric analysis of arterial cross-sections revealed that delivery of Ad.ATF.BPTI to the carotid artery wall at the time of balloon injury inhibited neointima formation by 53% (P Ͻ 0.01) at 14 days and 19% (P = NS) at 28 days after injury when compared with control vector-infected arteries. Intima/media ratios were decreased by 60% (P Ͻ 0.01) and 35% (P Ͻ 0.05) at 14 and 28 days, respectively, when compared with control vector-infected arteries. Furthermore, a small but significant increase in medial area was found in the Ad.ATF.BPTI-treated arteries at 28 days (P Ͻ 0.05). These results show that local infection of the vessel wall with Ad.ATF.BPTI reduces neointima formation, presumably by inhibiting SMC migration, thereby offering a novel therapeutic approach to inhibiting neointima development. Gene Therapy (2001) 8, 534-541.
Migration of cells within tissues requires controlled
proteolytic degradation of the ECM that encages them. Several proteolytic enzyme systems are thought to play a role in these processes, in particular the plasminogen activation (PA) system and the matrix metalloproteinase (MMP) system. The present study focuses on the PA system. The central action in the PA system is activation of plasminogen to plasmin by the plasminogen activators urokinase-type PA (u-PA) and tissue-type PA (t-PA). While the action of t-PA is to activate fibrinolysis within the blood circulation and body cavities, u-PA acts more locally at the cell surface. To that end, u-PA binds to a specific cell surface receptor, uPAR, which restricts the activity of u-PA to the direct cell environment and brings it in close contact to plasminogen on its receptor, allowing the efficient activation of plasminogen to plasmin at the cell surface. Receptor-bound u-PA is accessible to, and its activity predominantly inhibited by, plasminogen activator inhibitor type-1 (PAI-1). However, cell surface-bound plasmin is rather inaccessible for inhibition by its natural inhibitors ␣ 2 -antiplasmin and ␣ 2 -macroglobulin. 16 In vitro migration of SMC can be suppressed by inhibition of plasminogen activation or plasmin activity, by inhibition of u-PA activity, and by interfering with the 535 binding of u-PA to its receptor. [17] [18] [19] Studies in ballooninjured rat carotid arteries have shown increases in u-PA, t-PA, PAI-1, uPAR and overall plasmin activity at early times following arterial denudation, correlating with the migration of SMC from the media. 20 Treatment with the plasmin inhibitor tranexamic acid significantly reduced the migration of SMC in this model 21 as did the serine protease inhibitor FUT-175. 22 Furthermore, Carmeliet et al 23, 24 have shown that in u-PA and plasminogen knockout mice, neointima formation and neointimal cell accumulation were strongly reduced. In contrast, in PAI-1 knock-out mice, neointimal lesion formation was significantly increased and this was reversed by intravenous injection of adenovirus-expressing human PAI-1. 25 We recently reported on the construction of an adenoviral vector encoding the hybrid protein ATF.BPTI. 26 This vector encodes the active domain of bovine pancreas trypsin inhibitor (BPTI), also known as aprotinin, a potent inhibitor of plasmin, linked to the receptorbinding aminoterminal fragment (ATF) of u-PA. The secreted hybrid protein, ATF.BPTI, was found to inhibit SMC migration effectively in vitro and to be more potent than ATF or BPTI individually. In the present study, we describe the effects of local expression of the cell surfacebinding plasmin inhibitor ATF.BPTI, on neointima formation and luminal stenosis in balloon-injured rat carotid arteries.
Results
uPAR-bound plasmin inhibition by ATF.BPTI To demonstrate that ATF.BPTI is able to inhibit plasmin activity at the cell surface, mouse LB-6 cells expressing human uPA receptor (LB-uPAR), were incubated for 1 h with conditioned medium from CHO cells expressing ATF.BPTI. After extensive washing, cell extracts were prepared and the plasmin inhibitory capacity was determined. Plasmin activity in LB-uPAR cells was dose dependently reduced to 13.3 ± 3.2% of control at the maximum concentration of 4 g/ml ATF.BPTI ( Figure  1a) . Binding of u-PA to its receptor uPAR is reversible and receptor-bound u-PA can be removed by a mild acid (glycine buffer) treatment of the cells, before preparation of cell lysates. This feature was used to demonstrate further that functional ATF.BPTI was bound to the uPAR on the cells. Plasmin activity returned almost to baseline levels in the lysates of the acid-treated LB-uPAR cells.
In a second experiment, rat aortic smooth muscle cells (RASMC) cells were incubated with dilutions of conditioned medium from CHO cells infected with an adenovirus encoding a murine uPAR-binding variant of ATF.BPTI (Ad.mATF.BPTI) (Figure 1b) . As a control, dilutions of conditioned medium from Ad.LacZ-infected CHO cells were prepared. Whereas incubation with mATF.BPTI-conditioned medium strongly reduced plasmin activity in RASMC extracts to 3.9 ± 0.2% of control, no effects were seen with medium from Ad.LacZ-infected CHO cells. Acid treatment strongly increased plasmin activity in the mATF.BPTI group to 65% and 48% of control for the 1/16 and 1/8 dilutions, respectively. These results indicate that ATF successfully anchors BPTI to the uPAR, where it can inhibit plasmin activity at the cell surface. In vivo gene transfer and expression of ATF.BPTI mRNA In a previous study we described the effects of Ad.ATF.BPTI on human saphenous vein SMC migration and proliferation in vitro. 26 Whereas ATF.BPTI was found to be a strong inhibitor of cell migration, no significant effect on SMC proliferation was detected. The effects of inhibiting cell migration on neointima formation in vivo were assessed using the rat carotid artery balloon injury model. Balloon injury of rat carotid artery results in the development of a thickened intima on account of SMC migration from the media and proliferation in the intima. 27 This was confirmed by immunohistochemical staining for ␣SMC-actin of an uninjured artery and at 2 weeks after injury (Figure 2a, b) .
To demonstrate the in vivo efficacy of ATF.BPTI, the newly constructed murine variant of Ad.ATF.BPTI was used (Ad.mATF.BPTI). We first assessed whether Ad.mATF.BPTI could be efficiently delivered to ballooninjured rat carotid arteries. Rat carotid arteries were transfected with 100 l of 10 10 p.f.u./ml Ad.mATF.BPTI or control vector Ad.P10 for 30 min directly following balloon injury. The transfected arteries were harvested 4 days after infection, embedded in paraffin and sectioned. At four days after injury neointimal thickening was not yet detectable. The presence of ATF.BPTI mRNA was infected with 100 l of 10 10 p.f.u./ml Ad.mATF.BPTI or Ad.P10 after balloon injury. The transfected arteries were harvested at 4 and 28 days after infection, snap-frozen, crushed and extracted. Whereas no signal was detected in the Ad.P10-infected artery extracts, Ad.mATF.BPTIinfected arteries gave a strong but variable signal at 4 days, corresponding to a mean concentration of 20.2 ± 9.6 ng u-PA/mg protein. At 28 days after infection mATF.BPTI levels had decreased to 0.9 ± 0.6 ng u-PA/mg protein ( Figure 4 ).
Plasmin inhibitory activity was measured in the 4-days post-infection artery extracts to assess the functionality of the recombinant protein ATF.BPTI in the vessel wall ( Figure 5 ). Although both Ad.P10 and Ad.mATF.BPTIinfected artery extracts inhibited plasmin activity, as expected due to the abundant presence of intrinsic ␣ 2 - antiplasmin activity in the vessel wall, 28 this reduction was slightly larger in extracts of Ad.mATF.BPTI-infected arteries (17 ± 7% in the P10 group compared with 23 ± 9% in the mATF.BPTI group). However, these differences were not significant.
Effects of mATF.BPTI in balloon-injured rat carotid arteries
We next assessed whether local infection with Ad.mATF.BPTI inhibits intimal lesion formation in injured arteries. Animals were divided over three groups (n = 5) and treated with 100 l of vehicle only, 10 10 p.f.u./ml control vector Ad.P10, or 10 10 p.f.u./ml Ad.mATF.BPTI. Histological examination of cross-sections from control uninfected injured carotid arteries at 14 days after injury, showed appreciable development of neointimal areas when compared with uninjured arteries. Representative sections are shown in Figure 6a , b. Infection with Ad.P10 slightly increased neointima formation, whereas neointimal mass appeared strongly reduced after infection with Ad.mATF.BPTI (Figure 6c, d ). Microscopic observation showed no major histological differences between arteries subjected to injury alone and arteries subjected to both injury and control adenovirus (Figure 6b and c) .
To quantify the apparent reduction seen in the Ad.mATF.BPTI-infected group, neointimal and medial areas of arteries 14 days after injury were determined by digital image analysis of 12 sections from each arterial segment. The mean neointimal areas in the three groups are depicted in Figure 7a . The Ad.mATF.BPTI-infected arteries developed an intimal area of 0.041 ± 0.01 mm 2 (mean ± s.e.m.) whereas control uninfected and Ad.P10-infected arteries developed 0.078 ± 0.008 mm 2 and 0.089 ± 0.01 mm 2 for the control, Ad.P10 and Ad.mATF.BPTI groups, respectively) as shown in Figure  7b . The suppression of intimal area by mATF.BPTI was associated with a significantly decreased intima/media ratio of approximately 58% with respect to uninfected arteries and 60% with respect to Ad.P10-infected arteries (Figure 7c) . Finally, luminal stenosis of Ad.ATF.BPTIinfected arterial segments was limited to 17.9%, whereas uninfected and Ad.P10-infected controls had luminal stenoses of 34.1% and 34.6%, respectively (Figure 7d ). Although variability in inhibition of neointima formation in the mATF.BPTI-treated animals was observed, in all animals tested the neointima was significantly smaller than in the control groups. No statistical differences were found between uninfected arteries and arteries infected with Ad.P10 for all parameters described.
In a next set of experiments the effect of Ad.mATF.BPTI on neointima development 28 days after injury was examined (Figure 8 ). At this time, there was 18.8 ± 11.6% inhibition of neointima formation in Ad.mATF.BPTI-infected (0.166 ± 0.024 mm 2 ) when compared with Ad.P10-infected (0.204 ± 0.029 mm 2 ) carotid arteries, however, this difference did not reach statistical significance (Figure 8a) . Interestingly, as depicted in Figure 8b , a significant difference was noted when medial areas were compared at this time-point (0.113 ± 0.016 mm 2 and 0.139 ± 0.020 mm 2 in the Ad.P10-and Ad.mATF.BPTI-infected arteries, respectively, P Ͻ 0.05). The decrease in intimal area and increase in medial area resulted in a significantly decreased intima/media ratio of 34.6 ± 9.4% (P Ͻ 0.05) in the Ad.mATF.BPTI group (Figure 8c ). In addition, luminal stenosis was decreased by 23.7 ± 11.0% in the Ad.mATF.BPTI-infected arteries when compared with the Ad.P10-infected controls ( Figure 8d) ; however, this difference did not reach statistical significance. 2 
Figure 8 Quantitative morphometric analysis of Ad.mATF.BPTI-infected carotid arteries at 28 days after injury. Neointimal areas (a) and medial areas (b), expressed in mm

, intima/media ratios (c), and percentage luminal stenosis (d) 28 days after balloon injury to rat carotid arteries (n = 4) were quantified by image analysis of multiple cross-sections of the segments. Parameters are given in mean ± s.e.m. *P Ͻ 0.05 compared with Ad.P10 control adenovirus as determined by the Mann-Whitney test.
Discussion
In this study we demonstrate that inhibition of SMC migration in a rat arterial injury model using local adenoviral expression of the novel protease inhibitor ATF.BPTI, results in suppression of neointima development after endovascular injury.
In vivo gene delivery aimed to inhibit SMC proliferation has been used successfully to inhibit neointima development in the rat arterial injury model in various studies. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, experimental studies have shown that apart from proliferation, migration of SMC plays an important role in neointima formation after arterial injury. 29, 30 Previous analysis of the rat model suggested that 50% of neointimal cells are derived from proliferation and 50% from migration, 31 suggesting that complete inhibition of neointima formation will require intervention in both processes.
Vascular SMC migration depends on the action of extracellular proteolytic enzymes which modify cell matrix contacts and degrade extracellular matrix proteins. Two proteolytic systems are involved in this process: the plasminogen activation system and the matrix metalloproteinases (MMPs). Much research has been directed towards unraveling the role of the plasminogen activation system in cell migration. Pericellular proteolysis is attained by binding of u-PA to its receptor, uPAR, which is up-regulated in migrating cells. 32 This allows for the efficient activation of plasminogen to plasmin on its receptor and localized proteolytic activity. [33] [34] [35] The effects of plasmin inhibition on cell migration in vivo has been demonstrated by treatment with the synthetic plasmin inhibitors tranexamic acid and FUT-175, which strongly reduced cell migration and neointima formation in injured rat carotid arteries. 21, 22 The present study describes a gene therapy approach to inhibiting plasmin activity, cell migration and neointima formation in vivo.
We recently reported on the construction of an adenoviral vector encoding a novel hybrid protein ATF.BPTI. 26 Expression of this u-PA receptor-binding plasmin inhibitor in human saphenous vein SMC effectively inhibits SMC migration in vitro whereas no significant effect on proliferation was found. Furthermore, ATF.BPTI was found to be a more potent inhibitor of SMC migration than ATF or BPTI individually. Therefore, we hypothesized that adenoviral delivery of ATF.BPTI to the carotid artery at the time of injury would inhibit localized proteolysis, thereby blocking cell migration and inhibiting neointima formation.
The murine variant of ATF.BPTI, mATF.BPTI, was shown to bind rat aortic SMC and inhibit plasmin activity at the cell surface. Infection of carotid arteries with Ad.mATF.BPTI gave rise to strong expression of ATF.BPTI mRNA as was established by in situ hybridization with a BPTI-specific probe. In addition, high levels of ATF.BPTI protein, as measured by ELISA, were detected in vessel extracts 4 days after infection and at 28 days after infection low levels of ATF.BPTI protein could still be detected. Plasmin inhibitory action of ATF.BPTI in these extracts, however, was not significantly reduced when compared with control vectorinfected arteries. This may be explained by the presence of high intrinsic ␣ 2 -antiplasmin activity in the vessel wall, 28 creating a large amount of background plasmin inhibitory activity by vessel extracts per se. Since receptorbound plasmin is protected from inhibition by this ␣ 2 -antiplasmin activity, ATF.BPTI, able to bind to the cell surface, may have significant effects on plasmin activity at the cell surface although it could not be measured. This is supported by the data in Figure 1a showing strong plasmin inhibition by uPAR-expressing cells incubated with ATF.BPTI-containing medium, which was completely abolished after removing receptor-bound ATF.BPTI by mild acid treatment of the cells.
Infection with Ad.mATF.BPTI induced a strong reduction of neointimal development of approximately 50% at 2 weeks, which was associated with a reduction in intima/media ratio of approximately 60%. This degree of inhibition at 2 weeks exceeds the effects described after gene delivery of inhibitors of other proteolytic enzymes. Adenoviral gene transfer of the MMP inhibitor TIMP-1 reduced neointimal areas by 30% at 14 days after injury 36 and seeding of TIMP-1 overexpressing-SMC into the injured rat carotid artery reduced neointima formation by 25%. 37 Furthermore, the effects of TIMP-2 gene transfer were reduced to control levels by 21 days. 38 The increased efficacy of ATF.BPTI as opposed to these approaches during the initial 14 days after injury may reside in the fact that ATF.BPTI may achieve additional effects apart from its direct effect on plasmin activity. First, plasminogen activation is decreased by making the u-PA receptor less accessible for u-PA. Secondly, ATF.BPTI may inhibit plasmin-mediated activation of other matrix-degrading enzymes, such as pro-MMPs. Lijnen et al 39 showed that SMC migration and neointima formation after vascular injury are impaired in plasminogen and u-PA knock-out mice. In addition, no active MMP-9 was detected in plasminogen-deficient mice, indicating that its activity is critically dependent on activation 539 by plasmin as was reported before by Mazzieri et al. 40 Inhibiting plasmin activity may therefore be an approach to intervening early in the proteolytic cascade. At 28 days after injury, the inhibition in neointima accumulation in Ad.mATF.BPTI versus Ad.P10-treated carotid arteries was only 19% and did not achieve statistical significance. This 'catch-up' is accompanied by a 96% reduction of ATF.BPTI expression in the vessel wall. However, it is not clear whether the reduced inhibition is due to the loss of ATF.BPTI expression, since a similar 'catch-up' has been reported in recent studies using inhibitors of MMPs to prevent SMC migration and neointima formation in balloon-injured rat carotid arteries. 38, 41 Infection with Ad.TIMP-2 38 or systemic treatment with a synthetic MMP inhibitor 41 initially suppressed SMC migration but was followed by a catch-up phase leading to delayed neointimal lesion formation which was not significantly smaller than in control animals by 14 and 21 days, respectively. For now it can be concluded that short-term expression of ATF.BPTI is not sufficient to prevent longterm neointima formation. However, it cannot be excluded that the 'catch-up' might be associated with the general approach to preventing neointima formation by inhibition of protease activity and SMC migration. Furthermore, it remains to be analyzed what the effect of long-term ATF.BPTI expression will be, an issue that can be studied as soon as suitable vectors allowing prolonged gene expression will be available.
An interesting observation in our study was the significant increase in medial area of Ad.mATF.BPTI-treated arteries at 28 days. As a result of this increase, intima/media ratios for the Ad.mATF.BPTI-treated arteries were significantly reduced (35%) in the treated animals. This observation fits with the hypothesis that ATF.BPTI inhibits migration of SMC from the media to the intima after the first onset of neointima formation, thereby retaining SMC in the media.
The present study demonstrates that local adenoviral delivery of the cell surface-binding plasmin inhibitor ATF.BPTI at the time of arterial injury in rats has an inhibitory effect on neointimal development, thereby providing evidence of the role of plasmin activity in vascular SMC migration and the response to vascular injury. However, inhibition of migration alone will most likely not be able to inhibit neointima formation completely. It is therefore more likely that restenosis gene therapy will ultimately require inhibition of both cell migration and cell proliferation to achieve maximal suppression of neointima development. Adenoviral vectors designed to deliver inhibitors of proteolytic enzymes may then be combined with vectors encoding cell cycle inhibitors. Since localized plasmin inhibition appears to be an essential route to inhibiting migration of vascular SMC, ATF.BPTI constitutes an interesting candidate as therapeutic inhibitor of cell migration.
Materials and methods
Adenoviral vectors
Experiments described were performed using first generation E1-deleted recombinant adenoviral vectors derived from serotype 5 adenovirus using the cytomegalovirus (CMV) promoter/enhancer to drive transgene expression. The construction of a human variant of
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Ad.ATF.BPTI has been described. 26 Due to the speciesspecific nature of the binding of u-PA to its receptor 42 a murine variant of ATF.BPTI, mATF.BPTI, was constructed using the (Tyr22,Arg27,Arg29,Arg30) u-PA mutant cDNA 43 as starting material. A control adenoviral vector was constructed using the pCMV shuttle vector without insert as starting material (Ad.P10). , and streptomycin (100 g/ml)/penicillin (100 U/ml) (Biowhittaker, Verviers, Belgium).
Cell culture
Adenovirus production
Ad.mATF.BPTI and Ad.P10 were propagated on 911 cells and purified with CsCl as described previously. 44 Glycerol was added to a final concentration of 10% (v/v) and aliquots of 50 l virus stock were stored at −80°C. Virus stock titers (expressed in plaque forming units/mL, p.f.u./ml) were determined by plaque assay as described 44 and particle content of stocks by HPLC as described. 46 All adenovirus stocks used had comparable particle to p.f.u. ratios.
Plasmin inhibition assay
Recombinant protein activity was analyzed in a plasmin inhibition assay using the chromogenic substrate S2251 (Chromogenix, Mö lndahl, Sweden). Murine LB-6 cells expressing human u-PAR (LB-uPAR) were incubated with conditioned media of Ad.ATF.BPTI-infected CHO cells. In a second experiment, rat aortic smooth muscle cells (RASMC) were incubated with medium of Ad.mATF.BPTI-or Ad.LacZ-infected CHO cells. Removal of bound (m)ATF.BPTI from the u-PA receptor was performed by an acid treatment with 50 mmol/l glycin in 100 mm NaCl (pH 3.0). Cell extracts, made in PBS containing 0.5% Triton X-100, were incubated for 15 min at room temperature with a final concentration of 0.5 nm plasmin. After addition of S2251 the assay was incubated at 37°C and the A 405 was measured in time to determine the rate of conversion of the chromogenic substrate.
Balloon angioplasty and adenovirus infection in rat carotid arteries Male Sprague-Dawley rats weighing 350-450 g (IffaCredo, Someren, The Netherlands) were anesthetized by subcutaneous injection of 100 l Hypnorm (Janssen Pharmaceutica, Beerse, Belgium) followed by intraperitoneal injection of 6 mg/100 g body weight Nembutal (Sanofi Sante, Maassluis, The Netherlands). Routine balloon injury of common carotid artery was performed as described by Clowes et al 47 using a 2F-balloon catheter (Baxter, Lessines, Belgium). The catheter was rotated while it was pulled back and this was repeated three times.
After arterial injury and PBS flushing of the isolated arterial segment, 100 l adenovirus solution in PBS was injected into the lumen of the isolated artery via a fixed catheter. The control vector group received 10 10 p.f.u./ml Ad.P10, the Ad.mATF.BPTI vector group received 10 10 p.f.u./ml Ad.mATF.BPTI, and the control uninfected animals received 100 l 1% glycerol in PBS, corresponding to the glycerol concentration in the adenovirus groups. After 30 min, the vector solution was withdrawn and the artery gently rinsed again with PBS. Adenovirus concentrations were chosen in accordance to the described optimum for rat carotid artery infection. 48 Fixation and histological evaluation All rats were killed by lethal doses of anesthesia. At time of death, none of the animals had clinical evidence of wound infection and all common carotid arteries were patent. For assessment of transgene expression, carotid arteries from Ad.P10-infected rats and Ad.ATF.BPTIinfected rats were quickly harvested, rinsed of blood and either snap-frozen in liquid nitrogen for analysis by ELISA or embedded in paraffin for in situ hybridization.
The remaining rats in each treatment group were killed at 14 or 28 days after injury, after which the vessels were perfusion fixed in situ. Normal saline solution was instilled first, followed by 3.7% formalin in PBS. After overnight fixation in formalin solution carotid arteries were embedded in paraffin, sectioned (5 m), and stained with hematoxylin/eosin for microscopic examination or with Weigert's elastin stain for morphometric measurements.
Sections used for immunohistochemistry were preincubated with 0.3% H 2 O 2 and 0.1% sodium azide in PBS for 15 min to eliminate endogenous peroxidase activity, after which they were rinsed with PBS. Sections were incubated overnight at 4°C with a monoclonal antibody which recognizes smooth muscle ␣-actin (Sigma, Zwjndrecht, The Netherlands) at a 1:1000 dilution. Bound monoclonal antibodies were detected using horseradish peroxidase (HRP)-conjugated rabbit anti-mouse antibodies (1:300, DAKO, Glostrup, Denmark). Antibodies were diluted in PBS with 0.1% bovine serum albumin. Sections were exposed for 4 min to 0.04% diaminobenzidine tetrahydrochloride (DAB) in 0.05 mol/l Trismaleate buffer (pH 7.6) with 0.006% H 2 O 2 and counterstained with hematoxylin. The cross-sectional areas of neointima and media were measured using LeicaQwin image analysis system (Leica Imaging Systems, Cambridge, UK) on 12 evenly distributed Weigert's elastin-stained sections from each arterial segment. Neointimal area is calculated by subtracting the medial and luminal areas from the total area within external elastic membrane. Percentage luminal stenosis is calculated as percentage neointimal area of total area within internal elastic membrane.
In situ hybridization ATF.BPTI was probed using a 200 nucleotide riboprobe specific for the BPTI moiety synthesized as described 49 in the presence of 35 S-UTP (Amersham, Buckinghamshire, UK). Paraffin sections (5 m) of carotid arteries were mounted on 3-aminopropyltriethoxysilane-coated slides. In situ hybridization was performed as described. 49 Slides were developed in Kodak D19 (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) after an exposure of 6 days, fixed in Kodak UNIFIX, and counterstained with eosin and hematoxylin.
ELISA of ATF.BPTI Four snap-frozen carotid arteries were crushed on liquid nitrogen and submerged in 550 l lysis buffer (0.1% Triton X-100 in PBS) per vessel and incubated for 30 min at 4°C before centrifugation (4000 r.p.m., 10 min). Supernatants were stored at −80°C until measured by ELISA. A specific ELISA for ATF.BPTI was set-up using a monoclonal antibody against the aminoterminal fragment of u-PA 50 as a catching antibody and a rabbit polyclonal against aprotinin (a kind gift of Dr J Emeis, Gaubius Laboratory, Leiden, The Netherlands) as a detecting antibody. For quantification of ATF.BPTI a standard of ATF.BPTI was prepared, of which the ATF concentration was determined using a u-PA ELISA. 50 Amounts of ATF.BPTI protein are expressed in ng/ml u-PA per milligram protein, as determined by BCA protein assay on vessel extracts (Pierce, Rockford, IL, USA).
Statistics
Statistical analysis of morphometric measurements was performed by the Mann-Whitney test for variables with a non-parametric distribution. The Ad.mATF.BPTI group was compared with the control uninfected and Ad.P10-infected group and a value of P Ͻ 0.05 was considered significant.
